Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity …
$2.32-2.52%
报价 2026-11-13
市值
$295.5M
EV
$424.8M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -41.3%
$0.85$3.95
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-12不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NAUTNautilus Biotechnology, Inc. | $295.5M | -2.5% | -61.1% | -362.5% | – | – | – | |
| ASMBAssembly Biosciences, Inc. | $432.5M | +4.7% | +70.9% | 72.9% | 54.5x | – | – | |
| SGMTSagimet Biosciences Inc. | $333M | -6.5% | -90.0% | 0% | – | – | – | |
| ENTAEnanta Pharmaceuticals, Inc. | $320.1M | -1.9% | -6.6% | 100% | – | – | – | |
| ARCTArcturus Therapeutics Holdings Inc. | $241M | -0.9% | -81.3% | 24% | – | – | – | |
| IMRXImmuneering Corporation | $240.3M | +1.1% | +1836.4% | 0% | – | – | – | |
| PYXSPyxis Oncology, Inc. | $189M | -3.7% | -100.0% | 99.8% | – | – | – | |
| HUMAHumacyte, Inc. | $155.1M | -6.2% | +174.1% | -533% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $124.1M | +1.0% | -18.9% | 99.1% | 29.9x | 8.0x | – | |
| 同行中位数 | – | – | -12.8% | 48.5% | 42.2x | 8.0x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。